Home | K36tx
WEBOur Work. K36’s lead candidate is KTX-1001, a first-in-class, selective inhibitor of the histone methyltransferase (HMT) MMSET, which is overexpressed in up to 20% of multiple myeloma patients due to the t (4;14) translocation. We developed KTX-1001 to provide a targeted therapy that specifically addresses the underlying cause of cancer for ...
K36 | The Bar & Rooftop
WEBK36は京都・清水小学校校舎をリノベーションした「The Hotel Seiryu Kyoto Kiyomizu」最上階のThe Barと屋上のRooftop Bar。 京都の街を360度見渡せる絶好のロケーションです。
K36 Therapeutics announces dosing of first patient in KTX-1001 …
WEBCAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- K36 Therapeutics ("K36"), a privately held biotechnology company developing KTX-1001, an investigational small molecule methyltransferase inhibitor ...
K36 Therapeutics Launches with $30 Million Series A Financing …
WEBCAMBRIDGE, Mass., Dec. 9, 2021 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held biotechnology company developing breakthrough therapies for the unmet medical needs of cancer...
K36 Therapeutics Named “Overall BioPharma Startup of the Year” …
WEBCAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (“K36”) has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards ...
Our Science | K36tx
WEBAbout KTX-1001. KTX-1001 is an oral, first-in-class, selective MMSET catalytic inhibitor that suppresses H3k36me2 in patients with relapsed and refractory multiple myeloma (RRMM) with a focus on patients with the t (4;14 ) genetic translocation. This study will evaluate the safety, tolerability, and preliminary efficacy of KTX-1001.
About Us | K36tx
WEBLearn about K36tx, a biotech company dedicated to developing novel epigenetic therapies for cancer patients with unmet needs.
K36 Therapeutics Named “Overall BioPharma Startup of the
WEBCAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (“K36”) has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards ...
K36 emerges with $30M to bankroll multiple myeloma drug in …
WEBDec 9, 2021 · K36 Therapeutics has come out of the gates with $30 million in venture funding to back a small-molecule oral treatment from Novartis. The Cambridge, Massachusetts, biotech emerged Thursday to...
K36 Therapeutics Announces FDA Clearance of Investigational ... - BioSpace
WEBCAMBRIDGE, Mass., Aug. 23, 2022 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held biotechnology company developing novel targeted therapies for the unmet medical needs of cancer patients, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for the …
Skip to content